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Aims High-density lipoproteins (HDLs) are considered as anti-atherogenic. Recent experimental findings suggest that their
biological properties can be modified in certain clinical conditions by accumulation of serum amyloid A (SAA). The ef-
fect of SAA on the association between HDL-cholesterol (HDL-C) and cardiovascular outcome remains unknown.
Methods
and results
We examined the association of SAA and HDL-C with mortality in the Ludwigshafen Risk and Cardiovascular Health
(LURIC) study, which included 3310 patients undergoing coronary angiography. To validate our findings, we analysed
1255 participants of the German Diabetes and Dialysis study (4D) and 4027 participants of the Cooperative Health
Research in the Region of Augsburg (KORA) S4 study. In LURIC, SAA concentrations predicted all-cause and cardio-
vascular mortality. In patients with low SAA, higher HDL-C was associated with lower all-cause and cardiovascular
mortality. In contrast, in patients with high SAA, higher HDL-C was associated with increased all-cause and cardiovas-
cular mortality, indicating that SAA indeed modifies the beneficial properties of HDL. We complemented these clinical
observations by in vitro experiments, in which SAA impaired vascular functions of HDL. We further derived a formula
for the simple calculation of the amount of biologically ‘effective’ HDL-C based on measured HDL-C and SAA from the
LURIC study. In 4D and KORA S4 studies, we found that measured HDL-C was not associated with clinical outcomes,
whereas calculated ‘effective’ HDL-C significantly predicted better outcome.
Conclusion The acute-phase protein SAA modifies the biological effects of HDL-C in several clinical conditions. The concomitant
measurement of SAA is a simple, useful, and clinically applicable surrogate for the vascular functionality of HDL.
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Introduction
Cardiovascular disease (CVD) represents the major cause of death
in Western populations. In Europe, more than four million deaths
were caused by clinical complications of atherosclerosis such as
myocardial infarction or stroke in 2000.1 A variety of risk factors in-
cluding arterial hypertension, smoking, dyslipidaemia, obesity,
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diabetes mellitus, and chronic kidney disease (CKD) contribute to
the development of atherosclerotic vascular lesions.1– 3
In general, high-density lipoproteins (HDLs) are considered anti-
atherogenic.4,5 HDLs from healthy individuals have been shown to
stimulate endothelial nitric oxide (NO) production, to reduce
endothelial reactive oxygen species (ROS) production, and to
prevent pro-inflammatory responses of the endothelium. In vivo
administration of reconstituted HDL to hypercholesterolaemic
men has been demonstrated to improve endothelial function.6
Accordingly, observational trials have linked high concentrations
of HDL-cholesterol (HDL-C) to improve the cardiovascular
outcome.7
We and others have previously shown that HDLs may lose their
vasoprotective properties in disease conditions such as diabetes
mellitus, coronary artery disease (CAD), and CKD.8 – 12 Studies
examining the protein composition of HDL found that the acute-
phase protein serum amyloid A (SAA) may incorporate into the
HDL particle in disease conditions such as CAD or CKD.13 – 16 As
an acute-phase protein, SAA is also increased in patients with preva-
lent CVD.17,18
Although experimental evidence suggests that SAA may interfere
with vasoprotective properties of HDL,14 it is not clear whether in-
corporation of SAA into HDL may represent a common mechanism
by which the biological function of HDL is modified. Therefore, in
this study, we evaluated the effect of increasing concentrations of
SAA on the long-term prognostic value of HDL in one large cohort
of patients undergoing coronary angiography19 and validated our
findings in two additional cohorts with distinctly different subject
characteristics.20,21
Methods
Study populations
The Ludwigshafen Risk and Cardiovascular Health (LURIC) study en-
rolled 3316 patients undergoing coronary angiography between 1997
and 2000.19 3310 patients with all variables complete for current ana-
lyses were included. The study design and the examinations at baseline
have been described previously.19 The median follow-up time was 9.9
(8.5–10.7) years. All information on death during follow-up was ob-
tained from local Health Departments. Cardiovascular mortality was
defined as sudden cardiac death, fatal myocardial infarction, death due
to congestive heart failure, or death immediately after intervention to
treat CAD and fatal stroke.
The German Diabetes and Dialysis (4D) study is a prospective, ran-
domized, multicentre trial enrolling 1255 patients with type 2 diabetes
on haemodialysis for ,2 years between 1998 and 2002. The study de-
sign has been described in detail previously.20 The primary endpoint of
the 4D study was defined as the composite of cardiac death, non-fatal
myocardial infarction, and stroke, whichever occurred first (combined
cardiovascular events). Here, we analysed the primary endpoint of the
4D study as well as all-cause mortality.
The Cooperative Health Research in the Region of Augsburg (KORA)
S4 study is a population-based survey of inhabitants of Augsburg, Ger-
many including 4261 participants between 1999 and 2001. We excluded
subjects with previous myocardial infarction (n ¼ 77), stroke (n ¼ 48) or
with missing values for HDL-C or SAA (n ¼ 102), or those who were lost
to follow-up (n ¼ 7). Thus, 4027 participants were included in the present
analyses. Details of the study protocol have been described.21
LURIC, 4D, and KORA S4 studies were approved by the local Ethics
Committees and performed in accordance with the Declaration of
Helsinki. Informed consent was obtained from all participants.
Procedures
Detailed description is presented in Supplementary material.
Endothelial assays
The effect of HDL from healthy subjects (50 mg/mL) supplemented with
increasing concentrations of SAA on distinct endothelial functions (NO
and ROS production, vascular cell adhesion molecule-1 (VCAM-1) ex-
pression, and endothelial mononuclear cell adhesion) was determined
by incubating human aortic endothelial cells (HAEC) with HDL-SAA
preparations. For a detailed description, see Supplementary material.
Statistical analysis
The association among SAA, HDL-C, and their interaction (SAA×
HDL-C) with all-cause and cardiovascular mortality in the LURIC study
has been assessed using Cox regression analyses adjusted for age, sex,
acute coronary syndrome (ACS) at presentation, Friesinger coronary
score, body mass index, glycated haemoglobin, smoking, lipid-lowering
therapy, cystatin C, mean systolic blood pressure, and high-sensitivity
(hs) C-reactive protein. General linear models were used to estimate
the marginal means (adjusted) of SAA for several cardiovascular risk fac-
tors and disease states. A formula was built to calculate biologically ef-
fective HDL-C’ on the basis of measured HDL-C and SAA. Survival
analyses to examine the associations between calculated HDL-C’ and
distinct outcomes as indicated were performed in the 4D and KORA
S4 studies. Detailed information on the statistical methods is given in
Supplementary material.
Results
Baseline characteristics of the LURIC study are presented in Supple-
mentary material online, Table S1. During a median follow-up time
of 9.9 years, 995 participants (30.0%) died. About 66.5% (n ¼ 622)
of all deaths were caused by cardiovascular events.
We assessed the impact of increasing SAA on all-cause and
cardiovascular mortality. Supplementary material online, Figure S1
shows survival curves for all-cause and cardiovascular mortality,
according to quintiles of SAA. Higher SAA levels were signifi-
cantly associated with all-cause and cardiovascular mortality (both
P, 0.001). By Cox regression analyses (Supplementary material
online, Table S2), patients in the highest quintile of SAA had a sig-
nificantly increased risk for all-cause [hazard ratio (HR) 1.58; 95%
confidence interval (CI): 1.26–1.97] and cardiovascular mortality
(HR 1.72; 95% CI: 1.30–2.28) after adjustment for potential
confounders.
Recent experimental evidence suggests that SAA may be incor-
porated into HDL particles rendering HDL dysfunctional.13,14 To
examine the clinical relevance of these experimental findings, we as-
sessed the association of HDL-C with all-cause and cardiovascular
mortality at SAA concentrations above or below the 80th percentile
(16.9 mg/L) (Figure 1). HDL-C was inversely, dose-dependently, and
significantly associated with all-cause and cardiovascular mortality
below the 80th percentile of SAA after adjustment for potential
confounders. In marked contrast, at SAA above the 80th percentile,
HDL-C not only lost its ‘protective’ association with mortality, but
was also significantly and positively associated with all-cause and
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cardiovascular mortality. To analyse the interaction between
HDL-C and SAA, we performed Cox regression analyses including
the interaction term between HDL-C divided in quartiles and SAA
divided into two groups at the 80th (16.9 mg/L) or the 90th percent-
ile (42.9 mg/L) (Supplementary material online, Table S3). These
analyses revealed a significant interaction especially between
HDL-C in the highest quartile and SAA, suggesting that SAA may
modulate the biological effects of HDL.
Using the procedure described in Supplementary material,
an equation was derived, which allows for calculation of the ‘bio-
logically effective’ HDL-C′ concentration based on concomitantly
measured HDL-C and SAA concentrations:
HDL − C′ = 20 · 14(0 · 213 ∗ ln(ln(SAA) + 1)
+ (0 · 073 ∗ ln(ln(SAA) + 1) − 0 · 283)
NameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMeNameMe
HDL − C
√
− 0 · 176)2
Figure 1 HRs of all-cause and cardiovascular mortality according to HDL-C levels at high and low SAA concentrations in the LURIC study.
Multivariable-adjusted hazard functions for (A) all-cause and (B) cardiovascular mortality according to HDL-C concentrations at SAA below
and above 16.9 mg/L (80th percentile). Solid lines represent the hazard functions and dashed lines the respective 95% CIs. The median of
HDL-C (37 mg/dL) was chosen as reference (HR ¼ 1.0). Adjusted for age, sex, ACS, Friesinger score, body mass index, glycated haemoglobin,
smoking, lipid-lowering therapy, cystatin C, hs C-reactive protein, and mean systolic blood pressure. Green ranges represent the range of HDL-C
with a HR, 1 and red ranges with a HR . 1.
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The graph of the underlying function indicates that already slightly
elevated SAA is sufficient to substantially reduce the proportion
of biologically effective HDL-C (Figure 2 and Supplementary material
online, Table S4).
The acute-phase protein SAA can be associated with different
cardiovascular risk factors. Therefore, we next examined clinical
conditions associated with SAA (Table 1). Indeed, many cardiovas-
cular risk factors (e.g. diabetes, smoking, age, and renal impairment)
and manifest CVD (e.g. CAD and ACS) are related to significantly
elevated SAA after adjustment for heterogeneity. Patients with
angiographically proved CAD had more than two-fold higher SAA
levels than those without CAD, and in ACS patients SAA was
even increased more.
As renal impairment represents a potent cardiovascular risk fac-
tor and a clinical condition characterized by increased levels of SAA,
we validated the aforementioned algorithm in participants of the 4D
study. Baseline characteristics of the 4D study are shown in Supple-
mentary material online, Table S5. During a mean follow-up of 3.9
years, 37.3% of the study participants (n ¼ 469) reached the primary
endpoint and 49.1% (n ¼ 617) died from any cause. Using Cox re-
gression analyses, we determined the impact of measured HDL-C
and calculated biologically effective HDL-C′ on cardiovascular out-
comes (Supplementary material online, Table S6 and Figure 3).
HDL-C did neither associate with the primary composite endpoint
nor all-cause mortality. In contrast, calculated HDL-C′ was asso-
ciated with a significantly reduced risk for occurrence of the primary
composite endpoint as well as all-cause mortality.
Additionally, we analysed participants of the KORA S4 study.
Baseline characteristics are shown in Supplementary material
online, Table S7. During a mean follow-up of 11.0 (+1.7) years,
7.3% (n ¼ 294) of the study participants died, including 2.6%
(n ¼ 105) deaths due to cardiovascular events. In survival analyses,
measured HDL-C was not significantly associated with all-cause and
cardiovascular mortality. However, in marked contrast, calculated
biologically effective HDL-C′ significantly predicted all-cause
and cardiovascular mortality (Figure 4).
Finally, we addressed the mechanisms underlying these findings
on the cellular level by incubating cultured HAECs with HDL alone
and with HDL supplemented with different concentrations of
SAA. Although HDL alone significantly increased endothelial
production of NO, an important regulator of the vascular tone,
HDL supplemented with SAA not only lost its stimulatory effect,
but also significantly inhibited endothelial NO production in a
concentration-dependent fashion (Figure 5A). Vice versa, HDL sup-
plemented with SAA significantly increased endothelial production
of ROS, whereas HDL without SAA supplementation did not affect
basal endothelial ROS production (Figure 5B). HDL also significantly
reduced the expression of VCAM-1 on the surface of endothelial
cells in contrast to SAA-supplemented HDL (Figure 5C). Accord-
ingly, HDL significantly decreased the adhesion of mononuclear
cells to tumour necrosis factor alpha (TNF-a)-treated endothelial
cells (Figure 5D), whereas HDL supplemented with SAA lost this
inhibitory activity.
Discussion
We found a statistically significant association between the SAA
concentration and all-cause and cardiovascular mortality in a large
Figure 2 Calculation of biologically effective HDL-C′ by using HDL-C and SAA in the LURIC study. Graph of the function for the effective
HDL-C concentration hdlch′ ¼ hdlch′(saa,hdlch); isolines for hdlch′ ¼ 15, 20, 25, . . . ,50 mg/dL are projected onto the hdlch-saa plane; the effect-
ive HDL-C concentration hdlch′ ¼ f (saa,hdlc) (with f (x,y) ¼ 20.14(0.213ln(ln(x) + 1) + (0.073ln(ln(x) + 1)–0.283)y1/2–0.176)2) is evaluated on
the grid points (xi,yj) (I ¼ 0, . . . , 28 and j ¼ 0, . . . , 75), where xi ¼ 2.8 + 0.4i and yj ¼ 20 + 0.4j.
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cohort of patients with high cardiovascular risk. Even more import-
ant, our data provide strong evidence both in vivo and in vitro that
SAA transforms HDL from a protective into a noxious lipoprotein.
In subjects with elevated SAA, higher HDL-C was associated with
increased mortality, revealing that SAA significantly modifies vascu-
lar properties of HDL.
Atherosclerotic CVD is characterized by inflammatory reactions
of the vessel wall including accumulation of leucocytes.22 Consist-
ently, several acute-phase proteins such as C-reactive protein,
interleukin-6, or TNF-a have emerged as predictors for adverse
outcomes in patients with clinically manifest or subclinical
CVD.18,23 Previous studies have also linked elevated SAA to poorer
outcomes in patients with prevalent CVD.24,25 Interestingly, in this
study, higher SAA was not only associated with manifest CVD, but
also with several clinical conditions associated with increased car-
diovascular risk including CAD, diabetes mellitus, smoking, ageing,
and renal impairment.
Exactly in these conditions, HDL has been suggested to be dys-
functional, whereas HDL from healthy subjects preserves vascular
integrity and endothelial function.8,26 The molecular mechanisms
leading to dysfunctional HDL are only incompletely understood.
Alterations of the protein and lipid composition of HDL have docu-
mented to be crucially related to abnormal vascular function of
HDL.13,14 Indeed, we recently showed that HDL from patients
with CKD inhibits endothelial NO production and, thereby, in-
creases arterial blood pressure. It is in line with the current findings
that SAA accumulates in dysfunctional HDL particles of patients
with CAD and/or CKD,13,14 although the clinical relevance of these
findings has been elusive so far.
Therefore, we examined the association between HDL-C and all-
cause and cardiovascular mortality in patients with low and high
SAA. In patients with low concentrations of SAA, HDL-C was re-
lated to reduced all-cause and cardiovascular mortality. In marked
contrast, HDL-C was significantly and positively associated with all-
cause and cardiovascular mortality at high SAA, even after adjust-
ment for other inflammatory markers such as C-reactive protein.
These results suggest that even moderately elevated SAA
(.16.9 mg/L) is sufficient to substantially interfere with the benefi-
cial vascular properties of HDL. These findings may not only be rele-
vant to patients with CAD, as recent studies suggest,27 but to all
conditions that are associated with subclinical inflammation and,
concomitantly, elevated SAA such as diabetes, CKD, or smoking.
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Table 1 Association of cardiovascular risk factors and markers of disease severity with SAA concentrations in the
LURIC study
SAA (mg/L)a Mean difference, %
b
P-value
b
P-value
c
P-value
d
Acute coronary syndrome
No 17.1 (12.2–22.0)
Yes 57.1 (50.0–64.3) +234.1 ,0.001
Coronary artery disease
No 14.8 (6.1–23.5)
Yes 34.3 (29.4–39.2) +132.3 ,0.001
Chronic kidney disease
eGFR. 90 mL/min 24.3 (17.0–31.7)
eGFR 60–90 mL/min 28.8 (23.0–34.5) +10.3 0.353
eGFR ≤ 60 mL/min 43.0 (32.1–53.9) +43.4 0.008 0.019
Smoking
No 21.7 (15.3–28.2)
Yes 35.1 (29.5–40.7) +61.5 0.003
Diabetes
No 24.9 (19.3–30.6)
Yes 36.1 (28.7–43.4) +44.5 0.028
Sex
Female 26.4 (19.4–33.4)
Male 32.2 (27.6–36.8) +21.7 0.182
Age (years)
≤56.3 15.7 (7.3–24.0)
56.3–63.5 24.5 (16.6–32.4) +56.3 0.117
63.6–70.5 31.6 (23.7–39.4) +101.5 0.006 0.204
≥70.6 45.6 (37.7–53.5) +190.9 ,0.001 ,0.001 0.012
aEstimated marginal means and 95% CIs as calculated in a general linear model, adjusted for age, sex, lipid-lowering therapy, ACS, body mass index, mean systolic blood pressure,
cystatin C, glycated haemoglobin, Friesinger score, smoking, and hs C-reactive protein (where appropriate).
bComparison with the first category of each variable.
cComparison with the second category of each variable.
dComparison with the third category of each variable.
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Notably, our results led to the development of an algorithm that
can be used to calculate biologically effective HDL-C′. By using the
well-described 4D cohort of dialysis patients as well as the KORA S4
cohort, the clinical relevance of this formula was proved.20 Although
measured HDL-C had no significant impact on cardiovascular out-
comes as reported earlier,28 higher levels of the calculated biologic-
ally effective HDL-C′ were associated with reduced risk all-cause
mortality as well as cardiovascular endpoints. Although the LURIC
study includes patients at intermediate-to-high risk of CVD, KORA
represents the general population and 4D is a cohort with a very
high risk. Thus, our formula has been validated over a very broad
range of CVD risks from standard to extraordinary high.
Earlier studies have suggested that SAA might replace the main
structural protein of HDL apolipoprotein A–I, which may mediate
some of the vasoprotective properties of HDL.29 Additionally, the
accumulation of SAA in HDL was linked to reduced cholesterol ef-
flux capacity and anti-inflammatory activity of HDL.13,14 Moreover,
SAA-enriched HDL may be associated with the development of ath-
erosclerotic lesions in mice.30 In experimental studies, we observed
that SAA-supplemented HDL reduced endothelial NO production
and concomitantly increased endothelial production of ROS. Thus,
SAA turned HDL into a pro-inflammatory particle. These findings
underscore the important role of SAA in inverting the beneficial
vascular properties of HDL.
Our findings have several important clinical implications.
Currently, all assays to measure the biological properties of HDL
require time-consuming isolation of HDL by ultracentrifugation or
immunological methods. Our data suggest that concomitantly meas-
uring SAA and HDL may reflect the vascular function of HDL. This
may be of importance as a plethora of clinical conditions are asso-
ciated with inflammation and increased SAA. SAA, therefore, may
aid in the identification of patients with increased risk for cardiovas-
cular events, despite high HDL-C concentrations. Our algorithm to
calculate the effective HDL-C′ can be easily implemented in routine
diagnostics and can be used as a convenient tool to estimate the
functionality of HDL without time-consuming isolation of HDL
and demanding functional assays.
Efforts have recently been made to increase HDL-C by pharmaco-
logical means, e.g. using inhibitors of the cholesteryl-ester transfer
protein (CETP). Large trials using the CETP inhibitors torcetrapib
and dalcetrapib did not show a reduction of cardiovascular out-
comes.31,32 In these study programmes, a substantial proportion of
Figure 3 HRs of tertiles of measured and calculated biologically effective HDL-C for the primary composite endpoint as well as all-cause mortality
in the 4D study. HRs derived from multivariable Cox regression analyses adjusted for age, sex, body mass index, glycated haemoglobin, smoking
status, hs C-reactive protein, calcium, phosphate, duration of diabetes, hypertension, low-density lipoprotein, and medical treatment (placebo or
atorvastatin). $The primary composite endpoint comprises cardiac death, non-fatal myocardial infarction, and stroke. #Comparison with tertile 1.
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the patients had ACS, diabetes mellitus, and/or renal impairment,
i.e. conditions with increased SAA.32 Based on our findings, we specu-
late that raising HDL concentrations in patients with high SAA may be
detrimental. Measuring SAA could potentially help to identify patients
in whom HDL-increasing therapies may be advantageous. Although
speculative, the decrease of SAA seen during statin treatment33
may contribute to their atheroprotective effects and lowering may
turn out a useful approach to restore HDL functionality.
The main strengths of the present study are the large study po-
pulations with long-term follow-up. Accurate and comprehensive
clinical characterization of the participants made it possible to ad-
just for potential confounding variables. Confirmation of our re-
sults in the 4D study, including patients on dialysis treatment
with a high risk for cardiovascular events, as well as in the KORA
S4 study, comprising apparently healthy subjects in a population-
based setting, further supports our conclusions. The clinical
Figure 4 Univariate survival analyses for all-cause and cardiovascular mortality in the KORA S4 study according to quartiles of measured
and calculated biologically effective HDL-C′. Quartiles for measured HDL-C: quartile 1, ≤45.3 mg/dL; quartile 2, 45.3–55.7 mg/dL; quartile 3,
55.7–68.2 mg/dL; and quartile 4, .68.2 mg/dL. Quartiles for calculated biologically effective HDL-C′: quartile 1, ≤46.3 mg/dL; quartile 2,
46.3–61.3 mg/dL; quartile 3, 61.3–82.2 mg/dL; and quartile 4, .82.2 mg/dL).
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Figure 5 Endothelial effects of HDL supplemented with increasing concentrations of SAA. (A) Endothelial NO production as determined by elec-
tron spin resonance (ESR) spectroscopy in HAECs incubated with HDL (50 mg/mL) or HDL supplemented with SAA (100, 1000, or 2000 ng/mL) for
1 h. (B) Endothelial ROS production as determined by ESR spectroscopy in HAECs incubated with HDL (50 mg/mL) or HDL supplemented with SAA
(100, 1000, or 2000 ng/mL) for 1 h. (C) Endothelial VCAM-1 expression as determined by western blot in HAECs incubated with HDL (50 mg/mL) or
HDL supplemented with SAA (100, 1000, or 2000 ng/mL) for 5 h and TNF-a (0.1 ng/mL) for 4 h. (D) Adhesion of DiI-labelled THP-1 cells to HAECs
counterstained with DAPI and incubated with HDL (50 mg/mL) or HDL supplemented with SAA (100, 1000, or 2000 ng/mL) for 5 h and TNF-a
(0.1 ng/mL) for 4 h. n ¼ 5–7 per group. Respective means and standard deviation are shown. P-values have been adjusted for multiple comparisons.
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observations are further strongly supported by the mechanistic
cell culture studies. In summary, these findings indicate that the
concept of calculating biologically effective HDL-C′ may be applic-
able to patients with manifest, prevalent, and without CVD. Limita-
tions of our study are that the LURIC, 4D, and KORA S4 studies
primarily included patients of Caucasian ancestry, which limits
the extension of the present findings to other ethnicities. In add-
ition, despite careful analysis, confounding due to differences of
the baseline variables across SAA concentrations cannot be fully
excluded in a post hoc analysis. Additional studies are necessary
to determine the effect of different treatment strategies on the
interaction between SAA and HDL-C and to assess the perform-
ance of calculated biologically effective HDL-C′ in currently avail-
able scoring algorithms to predict cardiovascular risk. Moreover,
the time course and reversibility of SAA accumulation in HDL
have to be determined.
In conclusion, SAA is a strong marker for cardiovascular and
all-cause mortality, interacting with the functionality of HDL. SAA
transforms HDL from a vasoprotective into a pro-atherosclerotic
lipoprotein, which is associated with the substantially worsened
cardiovascular outcome at least partially mediated by promoting
endothelial dysfunction (Figure 6). Concomitantly measuring SAA
concentrations may represent a convenient method to estimate
HDL functionality in clinical routine.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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